高级检索
当前位置: 首页 > 详情页

Jiawei Yanghe Decoction suppresses breast cancer by regulating immune responses via JAK2/STAT3 signaling pathway

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, [2]School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China [3]Department of Oncology, Affiliated Dongguan People's Hospital, Southern Medical University, Dongguan, Guangdong, 523009, China. [4]School of Science, STEM College, RMIT University, Melbourne, Victoria 3000, [5]School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, 999077, China.
出处:
ISSN:

关键词: Modified Harmonious Yang Decoction Complementary and alternative medicine Chinese herbal medicine Natural products Breast carcinoma Inflammation

摘要:
Jiawei Yanghe Decoction (JWYHD) is a widely used traditional Chinese medicine prescription in the clinical setting for the treatment of autoimmune diseases. Many studies showed that JWYHD has anti-tumor activities in cell and animal models. However, the anti-breast cancer effects of JWYHD and the underlying mechanisms of action remain unknown.This study aimed to determine the anti-breast cancer effect and reveal the underlying mechanisms of action in vivo, in vitro and in silico.Orthotopic xenograft breast cancer mouse model and inflammatory zebrafish model were used to observe the anti-tumor effect and immune cell regulation of JWYHD. Moreover, the anti-inflammatory effect of JWYHD were evaluated by the expression of RAW 264.7 cells. JWYHD active ingredients were obtained by UPLC-MS/MS and potential targets were screened by network pharmacology. At last, the therapeutic targets and signaling pathways predicted by computer were assessed by western blot, real-time PCR (RT-PCR), immunohistochemistry (IHC) staining, and Enzyme-linked immunosorbent assays (ELISA) to explore the the therapeutic mechanism of JWYHD against breast cancer.JWYHD significantly decreased the tumor growth in a dose-dependent manner in the orthotopic xenograft breast cancer mouse model. Flow cytometry and IHC results indicated that JWYHD decreased the expressions of M2 macrophages and Treg while increasing M1 macrophages. Meanwhile, ELISA and western blot results showed a decrease in IL-1β, IL-6, TNFα, PTGS2 and VEGFα in tumor tissue of JWYHD groups. The results were also verified in LPS-induced RAW264.7 cells and zebrafish inflammatory models. TUNEL assay and IHC results showed that JWYHD significantly induced apoptosis. Seventy-two major compounds in JWYHD were identified by UPLC-MS/MS and Network pharmacology. It was found that the significant binding affinity of JWYHD to TNFα, PTGS2, EGFR, STAT3, VEGFα and their expression was inhibited by JWYHD. Western blot and IHC analysis confirmed that JWYHD plays an important role in anti-tumor and immune regulation by regulating JAK2/STAT3 signaling pathway.JWYHD exerts a significant anti-tumor effect mainly by inhibiting inflammation, activating immune responses and inducing apoptosis via the JAK2/STAT3 signaling pathway. Our findings provide strong pharmacological evidence for the clinical application of JWYHD in the management of breast cancer.Copyright © 2023. Published by Elsevier B.V.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 2 区 医学
小类 | 1 区 药学 1 区 全科医学与补充医学 1 区 植物科学 2 区 药物化学
最新[2025]版:
大类 | 2 区 医学
小类 | 1 区 全科医学与补充医学 1 区 药学 2 区 药物化学 2 区 植物科学
JCR分区:
出版当年[2021]版:
Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 PLANT SCIENCES Q2 CHEMISTRY, MEDICINAL Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 CHEMISTRY, MEDICINAL Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 PHARMACOLOGY & PHARMACY Q1 PLANT SCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, [2]School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China [3]Department of Oncology, Affiliated Dongguan People's Hospital, Southern Medical University, Dongguan, Guangdong, 523009, China.
共同第一作者:
通讯作者:
通讯机构: [1]Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, [2]School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China [3]Department of Oncology, Affiliated Dongguan People's Hospital, Southern Medical University, Dongguan, Guangdong, 523009, China. [*1]School of Traditional Chinese Medicine, Southern Medical University,Guangzhou, China [*2]Department of Oncology, Affiliated Dongguan People's Hospital, Southern Medical University, Dongguan, Guangdong, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号